admin

admin

Tyra Prices $400 Million Offering

Tyra priced an underwritten primary offering expected to raise approximately $400 million gross through common shares and nearly fully funded pre-funded warrants. The capital is earmarked for dabogratinib development across urothelial cancer and achondroplasia,…

Saturday Rounds: Week of September 6-11, 2026

Four approvals, a first-ever in-vivo CRISPR filing accepted with Priority Review, two high-profile pivotal misses, and roughly $1.6 billion of confirmed private financing — a week where mechanism mattered less than manufacturing, endpoint choice…